Who Paid My Doc
Benjamin Seeman
Interventional Pain Medicine Richmond, VA Doctor of Osteopathy
NPI 1750426987 CMS profile 170332
5901 W Broad St, Richmond, VA 23230
General payments
$21,169
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$7,255
Through program year 2025, Benjamin Seeman of Richmond, VA is reported in the CMS Open Payments database as having received $21,169 across 365 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $7,255 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 86th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,118 | 31 | |
| 2024 | General | $3,038 | 37 | |
| 2023 | General | $989 | 22 | |
| 2022 | General | $1,165 | 43 | |
| 2021 | General | $953 | 50 | |
| 2020 | General | $2,834 | 65 | |
| 2019 | General | $11,072 | 117 |
Beside peers
- Benjamin Seeman
- Interventional Pain Medicine median
- Middle half of Interventional Pain Medicine
- National median
In program year 2025, general payments to Benjamin Seeman were reported at $1,118. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.
Show as a table
| Year | Benjamin Seeman | Interventional Pain Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $11,072 | $684 | $216–$2,079 | $163 |
| 2020 | $2,834 | $382 | $122–$1,109 | $114 |
| 2021 | $953 | $552 | $167–$1,554 | $132 |
| 2022 | $1,165 | $605 | $187–$1,924 | $149 |
| 2023 | $989 | $671 | $195–$1,915 | $160 |
| 2024 | $3,038 | $684 | $206–$1,837 | $164 |
| 2025 | $1,118 | $657 | $184–$1,753 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 35 billing codesPaid by Medicare
$123,786
Medicare patients
166
Services billed
8,223
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Diabetes | 34% | |
| Depression | 34% | |
| Ischemic heart disease | 31% | |
| Chronic kidney disease | 27% | |
| Osteoporosis | 22% | |
| COPD | 20% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, methylprednisolone acetate, 80 mg J1040 | Office | 29 | 32 | $238 |
| Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 | Office | 111 | 710 | $206 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 86 | 124 | $12 |
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 38 | 40 | $4 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 9 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| Qutenza |
|
$38 | — | — |
| KRISTALOSE |
|
$30 | — | — |
| Xeomin |
|
$26 | — | — |
| HORIZANT |
|
$17 | — | — |
| Tirosint |
|
$12 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 9 in the dashboard with a free accountRecords
365 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Pain Medicine in Virginia
Ketan Patel
Interventional Pain Medicine · Haymarket, VA
Che Torry
Interventional Pain Medicine · Newport News, VA
Niteesh Bharara
Interventional Pain Medicine · Reston, VA
Sassan Hassassian
Interventional Pain Medicine · Manassas, VA
Raj Sureja
Interventional Pain Medicine · Newport News, VA
Alok Gopal
Interventional Pain Medicine · Winchester, VA
Related records
Interventional Pain Medicine in Virginia
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Pain Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Virginia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.